MT13 In-House Versus Send-out Next Generation Sequencing Testing for Metastatic Non-Small Cell Lung Cancer Patients. a Budget Impact Analysis
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.1660
https://www.valueinhealthjournal.com/article/S1098-3015(23)01760-6/fulltext
Title :
MT13 In-House Versus Send-out Next Generation Sequencing Testing for Metastatic Non-Small Cell Lung Cancer Patients. a Budget Impact Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01760-6&doi=10.1016/j.jval.2023.03.1660
First page :
Section Title :
Open access? :
No
Section Order :
11042